April 6, 2016, IBA -- IBA (Ion Beam Applications SA), the world’s leading provider of Proton Therapy solutions for cancer treatment, continues its leadership of Proton Therapy innovation and upgrades. Recently, the company installed a second Cone Beam CT (CBCT) at the University of Pennsylvania Health System, IBA’s longtime customer and research partner and pioneering facility of Proton Therapy. With most of its recent facilities equipped with CBCT, IBA remains the only Proton Therapy vendor with clinical CBCT at isocenter.

Penn Medicine's CBCT was installed in a gantry room equipped with Intensity Modulated Proton Therapy and powered by Pencil Beam Scanning, currently the world's most advanced radiotherapy treatment. This latest installation underscores IBA’s commitment to keep treatment systems up to date with our latest technology. With this new installation and with the prior installation of the world's first proton specific CBCT, Penn Medicine recognizes the importance of CBCT imaging for more precise treatment.

Sofie Gillis, Clinical Solution Director, IBA:
“IBA is committed to clinically relevant innovations that will help users to improve treatment quality. Developing and delivering CBCT is a key milestone in that respect. Combining volumetric imaging with pencil beam scanning will bring Proton Therapy to the next level.”

Alexander Lin, MD, Medical Director, Penn Medicine’s Roberts Proton Therapy Center:
“With CBCT, we continually adapt and personalize Proton Therapy throughout a patient’s treatment. This is a critical advance in improving the capabilities of Proton Therapy and ultimately improving patient outcomes.”

About the use of Cone Beam CT
As a component of IBA’s Image Guided Proton Therapy (IGPT) solution, CBCT provides volumetric imaging for increased accuracy in patient treatment. It is fully integrated with IBA’s imaging platform, adaPTinsight* and all commercial Oncology Information Systems. It offers fast 6D corrections of patient positioning for IBA’s Proteus®PLUS and Proteus®ONE Proton Therapy solutions.

Penn Medicine Center is currently examining the use of CBCT in adaptive Proton Therapy (reference: http://medicalphysicsweb.org/cws/article/research/64391).

*AdaPT Insight is the brand name of I2C, which is FDA cleared product.

Hospital Installs Homepage